Division of WerfenLife Group SA
Latest From Accriva Diagnostics
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.
Xagenic Inc.’s Amplified Redox Assay (AuRA) POC system utilizes chip-based arrays of microelectrodes to test samples for the presence of telltale nucleic acid strands. Because it is chip-based, it should be simple to run multiple tests on a single chip, and no sample extraction or preparation is needed to run the test.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
In Vitro Diagnostics
- Hematology, Coagulation
- Monitoring Equipment & Devices
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- ITC Nexus Holding Co.
- International Technidyne Corp.
- North America
- Parent & Subsidiaries
- WerfenLife Group SA
- Senior Management
Scott Cramer, Pres. & CEO
Greg Tibbitts, CFO
Matt Bastardi, SVP, Bus. Dev. & Strategy
Frank LaDuca, PhD, CSO
- Contact Info
Phone: (858) 404-8203
6260 Sequence Dr.
San Diego, CA 92121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.